TRAF2 and gastric cancer: In 190 MSI-H cancers with altered Bethesda MSI markers (48 CCs, 64 gastric cancers and 75 uterine endometrial cancers) [12], there are 6 TRAF2 mutations (5 gastric, 1 endometrial and 0 colon cancers; 3.2%) and 6 TRAF3 mutations (2 gastric, 2 endometrial and 2 colon cancers; 3.2%) with insertion or deletion in the 190 MSI-H cancers.